
    
      Identified patients who received curative surgery for stage I-III breast cancer and had
      available data on immunohistochemistry profiles including hormone receptor status (HR)
      status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung
      Medical Center from January 2004 to September 2008. Primary outcomes were recurrence-free
      survival (RFS) and overall survival (OS).
    
  